How Pharmacists Could Be Key to Addressing the Opioid Crisis

Optimal adherence to long-acting injectable buprenorphine (BUP-XR or Sublocade®) for opioid use disorder saves $15,017 per patient annually by drastically reducing costly emergency department visits and detoxification events. This research supports the economic benefits of paying community pharmacists to administer long-acting injections, effectively improving treatment access while lowering overall healthcare spending.